Publications
Detailed Information
In Vivo Scintigraphic Imaging of Antitumor Effects by Combined Radioiodine Therapy and Human Sodium Iodide Symporter Gene Immunotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Yun | - |
dc.contributor.author | Jeon, Yong Hyun | - |
dc.contributor.author | Paik, Jin Ho | - |
dc.contributor.author | Ko, Jinkyung | - |
dc.contributor.author | Chung, June Key | - |
dc.contributor.author | Kim, Chul Woo | - |
dc.contributor.author | Choi, Doe Han | - |
dc.date.accessioned | 2012-06-28T06:51:50Z | - |
dc.date.available | 2012-06-28T06:51:50Z | - |
dc.date.issued | 2010-06 | - |
dc.identifier.citation | MOLECULAR IMAGING; Vol.9; no.3; 141-152 | ko_KR |
dc.identifier.issn | 1535-3508 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77793 | - |
dc.description.abstract | In a previous study, we demonstrated that pcDNA3.1/hNIS (human sodium iodide symporter) vaccination generated hNIS-associated CD8(+)IFN-gamma(+) (interferon-gamma) T cells, which are known to be involved in antitumor immunity. However, the immune response induced was insufficient to control tumor growth in vivo, which required a novel approach to potentiate hNIS vaccination effects. In the present study, we administered (131)I radioiodine therapy prior to hNIS vaccination in CT26/hNIS tumor-bearing mice to facilitate the vaccine-induced immune response. We characterized hNIS-associated cytotoxic T-cell immune response and the antitumor effects induced by this (131)I + hNIS combination therapy. The survival rates of CT26/hNIS tumor cells were significantly reduced by (131)I treatment compared with the parental CT26 cells in vitro. (131)I + hNIS combination therapy stably suppressed tumor growth below or near the original tumor size level of initial treatment, achieving 100% survival rates. Specifically, (131)I + hNIS therapy enhanced IFN-gamma production, hNIS-associated antitumor cytotoxic T-lymphocyte (CTL) response, and induced more dendritic cells but reduced T-regulatory cells in tumor masses. Collectively, these results suggest that combined therapy effectively enhances hNIS-associated antitumor immune response, leading to CT26/hNIS tumor growth inhibition and complete survival in Balb/C mice. These findings provide a novel and effective means of treating cancer. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BC DECKER INC | ko_KR |
dc.title | In Vivo Scintigraphic Imaging of Antitumor Effects by Combined Radioiodine Therapy and Human Sodium Iodide Symporter Gene Immunotherapy | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 최윤 | - |
dc.contributor.AlternativeAuthor | 전용현 | - |
dc.contributor.AlternativeAuthor | 백진호 | - |
dc.contributor.AlternativeAuthor | 고진경 | - |
dc.contributor.AlternativeAuthor | 최도한 | - |
dc.contributor.AlternativeAuthor | 정준기 | - |
dc.contributor.AlternativeAuthor | 김철우 | - |
dc.identifier.doi | 10.2310/7290.2010.00010 | - |
dc.citation.journaltitle | MOLECULAR IMAGING | - |
dc.description.citedreference | Hwang DW, 2008, EUR J NUCL MED MOL I, V35, P135, DOI 10.1007/s00259-007-0561-8 | - |
dc.description.citedreference | Jeon YH, 2007, INT J CANCER, V121, P1593, DOI 10.1002/ijc.22837 | - |
dc.description.citedreference | Kim HJ, 2007, CANCER BIOL THER, V6, P1130 | - |
dc.description.citedreference | Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565 | - |
dc.description.citedreference | June CH, 2007, J CLIN INVEST, V117, P1466, DOI 10.1172/JCI32446 | - |
dc.description.citedreference | Choi Y, 2007, INT J CANCER, V120, P1942, DOI 10.1002/ijc.22567 | - |
dc.description.citedreference | Siddiqui SA, 2007, CLIN CANCER RES, V13, P2075, DOI 10.1158/1078-0432.CCR-06-2139 | - |
dc.description.citedreference | Wu TC, 2007, EUR J IMMUNOL, V37, P310, DOI 10.1002/eji.200636978 | - |
dc.description.citedreference | Kang TH, 2007, CANCER RES, V67, P802, DOI 10.1158/0008-5472.CAN-06-2638 | - |
dc.description.citedreference | Glasgow JN, 2006, CANCER GENE THER, V13, P830, DOI 10.1038/sj.cgt.7700928 | - |
dc.description.citedreference | Gelbard A, 2006, CLIN CANCER RES, V12, P1897, DOI 10.1158/1078-0432.CCR-05-1761 | - |
dc.description.citedreference | Wolf D, 2005, CLIN CANCER RES, V11, P8326, DOI 10.1158/1078-0432.CCR-05-1244 | - |
dc.description.citedreference | Li CW, 2005, CANCER GENE THER, V12, P913, DOI 10.1038/sj.cgt.7700876 | - |
dc.description.citedreference | Demaria S, 2005, INT J RADIAT ONCOL, V63, P655, DOI 10.1016/j.ijrobp.2005.06.032 | - |
dc.description.citedreference | Gulley JL, 2005, CLIN CANCER RES, V11, P3353 | - |
dc.description.citedreference | Scholz IV, 2005, GENE THER, V12, P272, DOI 10.1038/sj.gt.3302410 | - |
dc.description.citedreference | Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102 | - |
dc.description.citedreference | Kim KI, 2005, CLIN CANCER RES, V11, P123 | - |
dc.description.citedreference | Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093 | - |
dc.description.citedreference | Berzofsky JA, 2004, J CLIN INVEST, V113, P1515, DOI 10.1172/JCI200-421926 | - |
dc.description.citedreference | Shin JH, 2004, EUR J NUCL MED MOL I, V31, P425, DOI 10.1007/s00259-003-1394-8 | - |
dc.description.citedreference | Furumoto K, 2004, J CLIN INVEST, V113, P774, DOI 10.1172/JCI200419762 | - |
dc.description.citedreference | Doria-Rose NA, 2003, METHODS, V31, P207, DOI 10.1016/S1046-2023(03)00135-X | - |
dc.description.citedreference | Chakraborty M, 2003, J IMMUNOL, V170, P6338 | - |
dc.description.citedreference | Rosenberg SA, 2003, HUM GENE THER, V14, P709 | - |
dc.description.citedreference | Donnelly J, 2003, INT J PARASITOL, V33, P457, DOI 10.1016/S0020-7519(03)00056-0 | - |
dc.description.citedreference | Hung CF, 2003, CURR OPIN MOL THER, V5, P20 | - |
dc.description.citedreference | Gregoriadis G, 2002, VACCINE, V20, pB1 | - |
dc.description.citedreference | Chung JK, 2002, J NUCL MED, V43, P1188 | - |
dc.description.citedreference | Nikitina EY, 2001, INT J CANCER, V94, P825 | - |
dc.description.citedreference | Spitzweg C, 2001, GENE THER, V8, P1524 | - |
dc.description.citedreference | Spitzweg C, 2001, J CLIN ENDOCR METAB, V86, P3327 | - |
dc.description.citedreference | Dohan O, 2001, J CLIN ENDOCR METAB, V86, P2697 | - |
dc.description.citedreference | Schakowski F, 2001, MOL THER, V3, P793 | - |
dc.description.citedreference | Shi Y, 2000, P NATL ACAD SCI USA, V97, P14590 | - |
dc.description.citedreference | Spitzweg C, 2000, CANCER RES, V60, P6526 | - |
dc.description.citedreference | Tazebay UH, 2000, NAT MED, V6, P871 | - |
dc.description.citedreference | Boland A, 2000, CANCER RES, V60, P3484 | - |
dc.description.citedreference | Castellino F, 2000, J EXP MED, V191, P1957 | - |
dc.description.citedreference | Widera G, 2000, J IMMUNOL, V164, P4635 | - |
dc.description.citedreference | Castro MR, 1999, J ENDOCRINOL, V163, P495 | - |
dc.description.citedreference | Watters D, 1999, IMMUNOL CELL BIOL, V77, P263 | - |
dc.description.citedreference | Mandell RB, 1999, CANCER RES, V59, P661 | - |
dc.description.citedreference | Caillou B, 1998, J CLIN ENDOCR METAB, V83, P4102 | - |
dc.description.citedreference | Wang RB, 1998, SCIENCE, V282, P476 | - |
dc.description.citedreference | Boyle JS, 1998, NATURE, V392, P408 | - |
dc.description.citedreference | Sheard MA, 1997, INT J CANCER, V73, P757 | - |
dc.description.citedreference | KLEIN B, 1994, J NEUROSURG, V80, P1074 | - |
dc.description.citedreference | CARRASCO N, 1993, BIOCHIM BIOPHYS ACTA, V1154, P65 | - |
dc.description.citedreference | DONAHUE RE, 1992, J EXP MED, V176, P1125 | - |
dc.description.citedreference | GERMAIN RN, 1992, AIDS RES HUM RETROV, V8, P769 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.